AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2021
Sep 17, 2021
33390_dirs_2021-09-17_f9d5b8ee-cc0c-49d7-b037-9e6d12de9b14.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2021-09-15
Reporting Person: Jones Aranthan II (Chief Corp. Affairs Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-15 | Common Stock | M | 4277 | $12.27 | Acquired | 90962 | Direct |
| 2021-09-15 | Common Stock | M | 7842 | $11.32 | Acquired | 98804 | Direct |
| 2021-09-15 | Common Stock | S | 16824 | $16.488 | Disposed | 81980 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-09-15 | Employee Stock Option (Right to Buy) | $12.27 | M | 4277 | Disposed | 2029-07-24 | Common Stock (4277) | Direct |
| 2021-09-15 | Employee Stock Option (Right to Buy) | $11.32 | M | 7842 | Disposed | 2030-02-25 | Common Stock (7842) | Direct |
Footnotes
F1: A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
F4: The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date.